Why Aurora Therapeutics believes the FDA is ready for grouped CRISPR approvals
Can Aurora Therapeutics make CRISPR work at scale? Find out how its platform model for rare disease editing is testing biotech’s next big leap.
Pharma & Biotech
Pharma & Biotech
Can zetomipzomib move the needle in autoimmune hepatitis? What Kezar’s FDA meeting signals
Kezar is seeking FDA alignment for zetomipzomib in autoimmune hepatitis. Find out what’s at stake for trial design, safety, and strategic alternatives.
Pharma & Biotech
Why Biocytogen and Acepodia are betting on BsAD2Cs for next-gen cancer therapy
Biocytogen and Acepodia expand their ADC collaboration to evaluate dual-payload bispecifics. Find out how this model could reshape solid tumor therapy.
Pharma & Biotech
Can Clarametyx’s CMTX-101 reshape cystic fibrosis care by targeting biofilms?
Clarametyx’s CMTX-101 showed strong early signals in cystic fibrosis. Find out what this means for chronic lung infections and future bronchiectasis care.
Pharma & Biotech
AirNexis launches with $200m and Phase 2 dual PDE3/4 COPD drug licensed from Haisco
AirNexis launches with $200M and ex-China rights to AN01. Find out why this dual-pathway COPD therapy is drawing investor attention in 2026.
Pharma & Biotech
Why Naveris’s NavDx performance outcomes could alter HPV cancer follow‑up standards
See how Naveris’s NavDx ctHPV DNA results are reshaping HPV cancer surveillance and what this means for clinicians, payers, and precision oncology adoption.
Pharma & Biotech
Why Revvity’s Signals Xynthetica integration with Lilly TuneLab could reshape biotech AI
Revvity and Lilly team up to scale AI-powered drug discovery. Find out how federated learning could reshape access to predictive models across biotech.
Pharma & Biotech
Medipost raises $140m to fund U.S. Phase III trial of stem cell therapy for knee osteoarthritis
Medipost secures $140M to fund a pivotal U.S. Phase III trial in osteoarthritis. See how this could reshape the future of scalable stem cell therapies.
Pharma & Biotech
Eli Lilly taps Chai Discovery to accelerate biologics with AI-generated candidates
Eli Lilly partners with Chai Discovery to deploy AI for antibody drug design. Find out what this means for the future of biologics R&D.
Pharma & Biotech
Can Assertio win market traction with convenience-led G-CSF dosing schedules?
Can same-day dosing of Rolvedon reduce burden in breast cancer care? Explore new trial data, regulatory risks, and clinical impact in this detailed analysis.